GlassScriptPhysician profile
Linda Jill Moore
NPI 1134116106
$10,236.59
in general payments reported to CMS, 2019-2025
48 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,379 · 2020: $1,897 · 2021: $2,513 · 2022: $1,603 · 2023: $1,467 · 2024: $944 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,844.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,391.63 | 2019-2024 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,030.38 | 2020-2025 | |
| Lilly USA, LLC | $746.45 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $549.63 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $474.51 | 2019-2024 | Prolia, Evenity, Repatha |
| Esperion Therapeutics, INC. | $469.30 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $460.23 | 2019-2025 | Jardiance, Ofev |
| Radius Health, INC. | $371.91 | 2019-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $368.60 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $339.33 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $335.02 | 2019-2023 | Breztri, Farxiga |
| Astellas Pharma US INC | $295.77 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $294.17 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $290.55 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $284.13 | 2019-2024 | Trintellix |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.